CEL-SCI Corp. (AMEX: CVM) announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE